文献速递肾移植

移植前炎症标志物与活化CD8 T细胞可预测HIV阳性肾移植受者排斥风险

Pretransplant Levels of C-Reactive Protein, Soluble TNF Receptor-1, and CD38+HLADR+ CD8 T Cells Predict Risk of Allograft Rejection in HIV+ Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2019-08-19

前瞻性队列纳入22例HIV阴性供者至HIV阳性受者的肾移植受者,移植前检测炎症、微生物易位及T细胞活化标志物并随访急性排斥。移植前sTNF-R1、CRP及CD38+HLADR+CD8 T细胞水平较高者,活检证实的急性排斥累积发生率显著升高。提示可据此识别高危HIV阳性受者并个体化诱导免疫抑制。

要点

  • 移植前sTNF-R1或活化CD8+ T细胞高者200天活检证实急性排斥累积发生率为38%对0%(P=0.01)。
  • 移植前CRP>5 μg/ml与移植后6个月内急性排斥风险升高相关(43%对0%,P=0.01)。
  • 上述标志物或有助于HIV阳性肾移植受者的个体化诱导免疫抑制。

核心结论

  • 移植前sTNF-R1、CRP及CD38+HLADR+CD8 T细胞水平可预测HIV阳性肾移植受者的急性排斥风险。

研究设计与样本

  • 前瞻性队列研究,纳入22例HIV阴性供者至HIV阳性受者的肾移植受者,移植前评估生物标志物并随访急性排斥。

主要发现

  • 活检证实的急性排斥患者移植前sTNF-R1、CRP及CD38+HLADR+CD8 T细胞频率显著更高。
  • 移植前sTNF-R1或活化CD8+ T细胞高者200天活检证实急性排斥累积发生率为38%对0%(P=0.01)。
  • 移植前CRP>5 μg/ml者移植后6个月内急性排斥发生率为43%对0%(P=0.01)。

关键数值与推荐

  • sTNF-R1或CD38+HLADR+CD8 T细胞高:200天累积急性排斥发生率38%对0%,P=0.01。
  • CRP>5 μg/ml:移植后6个月内急性排斥发生率43%对0%,P=0.01。

临床怎么用

  • 对HIV阳性肾移植受者可在移植前检测sTNF-R1、CRP及活化CD8+ T细胞,识别排斥高危者以考虑个体化诱导免疫抑制。

局限性

  • 样本量仅22例,为单中心前瞻性队列,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: HIV-positive (HIV+) kidney transplant recipients exhibit a 2- to 3-fold increased risk of allograft rejection. Dysregulated immune activation in HIV infection persists despite successful antiretroviral therapy and is associated with non-AIDS morbidity, including renal disease. We hypothesized that the pathological levels of inflammation and immune activation associated with chronic HIV infection could have clinical utility in the prediction of rejection in HIV+ kidney recipients. METHODS: Prospective cohort study of 22 HIV-negative (HIV-; donor) to HIV+ (recipient) kidney transplant recipients who underwent biomarker assessment pretransplant and were subsequently followed for development of acute rejection. Plasma levels of markers of inflammation (soluble tumor necrosis factor receptor 1 [sTNF-R1] and C-reactive protein [CRP]) and microbial translocation (soluble CD14 and lipopolysaccharide) were measured by enzyme-linked immunosorbent assay or chromogenic endpoint assay. Levels of activated (CD38+HLADR+) CD4+ and CD8+ T cells, and T regulatory cells (CD4+CD25highFoxP3+) were measured by flow cytometry. RESULTS: Among the biomarkers evaluated, only the pretransplant levels of sTNF-R1, CRP, and frequencies of CD38+HLADR+ CD8 T cells, were found to be at significantly higher levels among patients who experienced biopsy-proven acute rejection. Confirming our hypothesis, patients with high pretransplant levels of sTNF-R1 or activated CD8+ T cells had a significantly increased 200-day cumulative incidence of biopsy-proven acute rejection (0 vs. 38% for both; P = 0.01). Similarly, pretransplant CRP levels higher than 5 μg/ml were associated with increased risk of acute rejection within the first 6 months post-transplant (0 vs. 43%; P = 0.01). CONCLUSION: Biomarker-based identification of HIV+ recipients at increased risk for rejection might facilitate individualized induction immunosuppression regimens in this vulnerable patient population.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Camargo JF, Pallikkuth S, Moroz I, et al. Pretransplant Levels of C-Reactive Protein, Soluble TNF Receptor-1, and CD38+HLADR+ CD8 T Cells Predict Risk of Allograft Rejection in HIV+ Kidney Transplant Recipients. Kidney Int Rep. 2019. PMID: 31844807. doi:10.1016/j.ekir.2019.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。